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The biology of the glomerulus: Endothelial cells
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The cluster of capillaries within the glomerulus (derived from
the Latin, "glomus", meaning ball) forms a highly organized
filtering unit which is comprised of the capillary endothelial
cells, the subjacent basement membrane and the podocytes,
while mesangial cells support the center of the structure and
directly contact the endothelial cells in places. As elsewhere
within the microcirculation, the glomerular endothelial cells are
exposed to all the circulating blood elements. Two basic ques-
tions therefore arise. First, to what extent do the specialized
fenestrated glomerular endothelial cells resemble other endo-
thelial cells of the microcirculation? Second, to what extent do
glomerular endothelial cells contribute to the development of
disease processes within the glomerulus? Unfortunately, it has
proved extremely difficult to isolate and culture human glomer-
ular endothelial cells to allow in vitro assessment of their
properties. Most of the present knowledge of the functional
properties of endothelial cells has been derived from the study
of cells grown from human umbilical veins. Therefore, by
necessity this article will consider data based on studies with
human umbilical vein endothelial cells, focusing largely on the
role of the endothelium in inflammation and immunity, before
returning to consider glomerular endothelial cells.
Functional properties of endothelial cells
Many of the functions of the vascular endothelium reflect its
position at the interface between blood and tissues.
Hemodynamically it functions as a permeability barrier and
contributes to the regulation of vasomotor tone through the
secretion of endothelin and platelet derived growth factor,
which stimulate vascular smooth muscle contraction [1, 2], and
through the secretion of nitric oxide and prostacyclin, which
stimulate smooth muscle relaxation [3, 4]. Within the glomeru-
lus, the permeability requirements are clearly different from
most endothelia elsewhere in the body because of the need to
develop an ultrafiltrate of plasma; the presence of fenestrae
bears witness to this. It is likely that glomerular endothelial
cells, like extraglomerular renal endothelial cells, produce
vasoregulatory compounds which can target the contractile
mesangial cells or the post-capillary arteriole.
The normal endothelium maintains the fluidity of the blood
via a number of mechanisms including the expression of throm-
bomodulin, secretion of protein S, expression of heparan sul-
fate anticoagulant, the ability to catalyze the activation of
plasminogen to plasmin, and the secretion of prostacyclin [5, 6].
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More recently it has been recognized that the endothelium is
integral to the development of inflammatory foci, both through
hemodynamic vasodilator effects and by recruitment of leuko-
cytes [7]. It is integral also to the normal functioning of the
immune system by its capacity to direct the normal recircula-
tion of lymphocytes around the body, by coordinating lympho-
cyte accumulation at sites of immune challenge and through
immune accessory cell activities [7].
Adhesive contact between the vascular endothelium and
circulating leukocytes is necessary for the recruitment of leu-
kocytes at sites of inflammation and for their subsequent
migration into tissues. Cytokines and inflammatory agonists
stimulate the cell surface expression and activate molecular
conformation of many of the molecules involved in these
adhesive interactions, thereby imposing time-dependent, site-
specific and leukocyte-specific levels of regulation on the re-
cruitment process. Adhesive contacts between endothelium
and lymphocytes are also important for certain immune acces-
sory functions of endothelial cells.
Molecules that mediate leukocyte-endothelial cell adhesion
Most of the molecules involved in adhesive interactions
between endothelial cells and leukocytes belong to either the
selectin family, the integrin family, or the immunoglobulin
superfamily [8, 9].
The selectin family contains just three members, L-, E- and
P-selectin; all three are involved in leukocyte-endothelial cell
adhesion. The selectins are transmembrane molecules with
short cytoplasmic tails. They have an N-terminal Ca2-depen-
dent lectin-like domain, followed by an epidermal growth
factor- (EGF-)like domain, and a variable number of domains
that have homology to complement regulatory proteins.
The integrin family is more extensive. Each member mole-
cule is an a3 heterodimer. Subfamilies are characterized by the
pchain (/31 through /38) and each /3 chain can pair with a variety
of different a chains. Fourteen a chains have been identified,
although the actual diversity of heterodimers is more restricted
than the potential diversity would suggest. Only a limited
number of integrin family members mediate cell-cell adhesion
(as against cell-substratum adhesion) by recognizing integral
membrane proteins of the immunoglobulin superfamily. These
include a4f31 (also known as VLA-4) and the three members of
the /32 subfamily: LFA-i (CD11a, CD18), MAC-l (CD11b,
CD18; Mo-i; CR3) and p1501g95 (CDllc, CD18). Both a and )3
subunits of integrin molecules are transmembrane glycopro-
teins; the a chain contains divalent cation-binding motifs and
requires Ca + or Mg + for function.
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Table 1. Endothelial and leukocyte adhesion molecules
Selectins
P-selectin
E-selectin
L-seiectin
Integrins
LFA- I
Mac-l
p150,95
VLA-4
Immunogiobulin superfamily
ICAM-l
ICAM-2
ICAM-3
VCAM-l
PECAM-l (CD31)
EC, platelets
EC
N, M, T subsets
All leukocytes
N, M
N, M, T subsets
M, T, B, E
EC, M, T, B, Foil DC
EC, M, T, B
N, M, T
EC
EC, M, T subset
Thrombin, histamine
IL-i. TNF, LT, LPS
IL-8, receptor-cross-
linking, PAF, others
MIB-l/3, others
IL-I, TNF, LT, IFN-y, LPS
Not induced
PHA
IL-l, TNF, LT, IL-4, LPS
Counterligand
Sialyl- Lewis' (CD15)
Sialyl- Lewis' (CDI5)
Others?
GLYcam-l (on HEV)
Others?
ICAM-i, -2, -3
ICAM-l, C3b, factor X, LPS
ICAM-I, others?
VCAM-l, fibronectin
LFA-l, MAC-I
LFA-l
LFA-l
VLA-4, a4/37
?CD31
Finally, the immunoglobulin superfamily contains some im-
portant endothelial adhesion molecules that are receptors for
integrin molecules. They include ICAM-l, ICAM-2, ICAM-3
(although ICAM-3 is not expressed by endothelial cells [10])
and VCAM-1. ICAM-1 and ICAM-2 are counter receptors on
endothelial cells (although their expression is not exclusive to
endothelial cells) for /32 integrins. LFA-1 and MAC-l bind
ICAM-l while only LFA-l binds ICAM-2. ICAM-l and -2 have
five and two immunoglobulin domains, respectively. They span
the membrane and both have cytoplasmic tails. VCAM-l has
seven immunoglobulin domains, although an alternatively
spliced form which lacks domain four also occurs naturally [11,
121. It is a counter-receptor for a4/31 (VLA-4) and possibly for
a4/37.
Receptor-ligand interactions are shown in Table I.
Mechanisms of leukocyte adhesion to endothelium at
inflammatory sites
Leukocyte adhesion at sites of inflammation is a multi-step
process. Initially leukocytes (and this has been best worked out
for neutrophils [13]) engage in low-affinity interactions with
selectin molecules expressed by the post-capillary venule
where shear rates are <600 s1, giving rise to the rolling
motions observed in time-elapse videos. The endothelial ex-
pression of P- and E-selectin is induced by inflammatory
mediators and cytokines (Table 1). Activation of neutrophil 132
integrins follows in which the leukocyte receives signals that
cause it to alter its /32 integrin conformation and receptor
binding affinity (inside to out signaling) [14]. This process may
be initiated by a number of leukocyte stimuli including inflam-
matory mediators produced by and present on the surface of
endothelial cells. Examples are platelet activating factor (PAF)
and some low molecular weight cytokines such as IL-8 and
MIP-1f3 [13, 15]. For neutrophils entering a new inflammatory
site, it is suggested that they roil on P-selectin (which can be
rapidly translocated to the endothelial cell surface following
appropriate stimuli) and are triggered to activate CD1 l-CD18 by
PAF; in contrast, neutrophils entering lesions a few hours old
(such as after 4 to 6 hours), roll on E-selectin (induced on
endothelial cells by de novo synthesis in response to IL-i and
TNF) and may be triggered to activate integrins by endothelial-
derived IL-8 [13]. In this way strong adhesion occurs between
integrin molecules and their counter receptors. Next, neutro-
phils migrate into tissues; the processes underlying this migra-
tion are poorly understood but involve integrins, since there is
no transmigration of neutrophils at sites of infection in patients
who have the LAD-i syndrome (leukocyte adhesion molecule
deficiency syndrome type 1) where leukocytes lack /32 integrin
expression [16]. Thus, there is an adhesion cascade which is
characterized by the timely induction or activation of adhesion
molecules. Specificity is inbuilt at several levels including
cell-specific expression of certain molecules or sets of mole-
cules, and critically on specific activation steps that are coor-
dinated in time and place.
T lymphocytes differ from neutrophils in their interactions
with endothelium on many accounts. First, T cells can interact
with non-inflamed endothelium to enter normal tissues, allow-
ing recirculation and homing to particular areas [17]. Second,
different lineages and subsets of T cells interact differently with
endothelium. Within the CD4 T-cell lineage are naive and
memory subsets: the naive subset mainly traffic to lymphoid
tissue, the memory subset to non-lymphoid tissues (skin, gut,
etc.) [18]. Memory T cells express higher levels of several
adhesion molecules including LFA-i, VLA-4, VLA-5 and
VLA-6 [18]. At sites of inflammation, "normal" interaction of T
cells with endothelial cells may be dramatically modified as a
consequence of the altered endothelial cell phenotype. As a
result, T cells demonstrate enhanced binding to endothelial
cells with a reduced tissue selectivity.
An appreciation of how levels of leukocyte and endothelial
cell activation may influence the use of different adhesion
pathways is illustrated by the binding of CD4 T cells and
endothelial cells under static conditions [19, 20]. Resting CD4
T cells show little binding (± on an arbitrary scale) to resting
endothelial cells, but show enhanced binding (+) to cytokine-
activated (IL-i for 4 hours) endothelial cells. This binding is
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Abbreviations are: EC, endotheliai cell; N, neutrophil; M, monocyte; E, eosinophii; T, T cell; B, B cell; HEy, high endothelial venules; Foil
DC, Follicular dendritic cell; PHA, phytohemagglutinin.
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largely mediated by a T cell ligand binding to E-selectin with
lesser contributions by LFA-1 binding to ICAM-! and ICAM-2
or VLA-4 to VCAM-1. Activation of T cells with PMA in-
creases binding to both resting (+ +) and activated endothelium
(+ + +). The activated T cells predominantly use LFA-l but the
reciprocal ligand used by endothelial cells depends on their
activation state, with ICAM-2 being used mainly by resting
endotheium and ICAM-l and -2 being used by activated
endothelium. In addition there is significant adhesion between
VLA-4 and VCAM-1 when both T cells and endothelial cells are
activated, as well as a contribution from an E-selectin depen-
dent pathway (reflecting activation of endothelium rather than T
cells). Within the CD4 I cell subset, the memory cells bind
better than naive cells and utilize all four adhesion pathways;
naive T cell adhesion is mediated predominantly by LFA-1.
CD8 naive or memory I cells probably differ from CD4 T
cells in the specifics of their interactions with endothelium. For
example, CD31 (another immunoglobulin supergene family
member) has been implicated in CD8 naive T cell adhesion
processes [20]. As with neutrophils, adhesion under flow con-
ditions in the post-capillary venule probably involves a se-
quence of events (the so-called adhesion cascade). It has been
suggested that lymphocytes may differ from neutrophils by
"colliding" with endothelium rather than rolling along it. How-
ever, as with neutrophils, initial adhesive events are probably
selectin-dependent since the majority of lymphocytes are in the
resting state (rather than in an activated state with functionally
active mtegrin molecules). Integnns may be triggered by a
variety of stimuli, as discussed for neutrophils, but in addition
there may be T cell specific stimuli. For example, it has been
shown recently that MIP-l/3, a low molecular weight cytokine
which can bind to endothelial cell surface proteoglycans, can
augment adhesion of CD8 T cells to VCAM-l [21].
Participation of endothelial cells in immune responses
Endothelial cells can participate in immune responses in at
least two ways. First, they direct the recirculation of lympho-
cytes around the body, allowing lymphocyte subsets to home to
particular lymphoid tissues or organs [171. It is likely that
homing is largely regulated by tissue-specific receptor-ligand
interactions between lymphocyte subsets and endothelium.
Recently, an endothelial ligand (or addressin) on mucosal
lymphoid tissue which is involved in lymphocyte homing,
MAdCAM-1, has been cloned and sequenced by the Butcher
group [22], while the endothelial lymph node addressin, Gly-
CAM-i, a ligand for L-selectin, has been characterized as a
mucin-like glycoprotein whose activity depends in sialyation,
fucosylation and sulfation of 0-linked chains [23]. Some skin-
homing CD4 T cells bind to ELAM-1 using the CLA antigen
[24]. So far, there is no information to suggest that particular
lymphocytes can home to glomeruli.
The second way in which endothelial cells may participate in
immune responses is through their immune accessory func-
tions. Endothelial cells are equipped to behave as semi-profes-
sional (non-bone-marrow derived) antigen-presenting cells for
CD4 T helper cells since they can express class II HLA-DR,
-DQ and -DP molecules, a prerequisite for presenting specific
antigenic peptides to the T cells [25]. Endothelial cells in culture
can be induced to express class II molecules by IFN-y [26],
while in vivo endothelial cells may constitutively express class
II molecules as has been documented for renal glomerular
endothelial cells [27]. A T cell whose receptors have been
engaged by the class Il/antigen complex on the surface of the
antigen-presenting cell and which has received this primary
signal must also receive costimulatory signals from the antigen-
presenting cell; in response, the CD4 T cell secretes enhanced
levels of effector cytokines (IL-2, IL-4 and IFN-y) which, in
turn, stimulate self-proliferation and help to recruit and activate
CD8 cytotoxic T cells [28]. There is evidence that endothelial
cells provide costimulation using the cell-surface molecule
LFA-3, which engages with T cell CD2 molecules when the
cells are in contact [29, 30]. In addition, signals transmitted by
the ligand-bound T cell receptor to T cell LFA-i may activate
this integrin to promote adhesiveness [31].
In vitro there is evidence from studies using allogeneic T
cells, that endothelial cells can activate both CD4 T cells, via
IFN-y induced class II molecules [32], and also CD8 T cells,
via constitutively expressed class I molecules (Note added in
proof). Our own recent studies using peptides derived from the
acetyicholine receptor a chain, suggest that endothelial cells
can present short peptides (<40 amino acid residues) and also
longer peptides (comprising 436 amino acid residues that must
require uptake and processing by the APC prior to presentation)
to both HLA-DR and -DQ restricted T cell lines and clones
(Savage et al, manuscript submitted).
Role of endothelial cells in glomerular diseases
The diverse functions of endothelial cells (and those within
the glomerulus are likely to be no less diverse) suggest that they
may affect, or be affected by, disease processes in many ways.
These include the promotion of hyperpermeability states to
solutes, the promotion of hypercoagulation within glomerular
capillary loops, and enhanced interactions with leukocytes.
Cytokines and procoagulant effects on endothelium
As discussed earlier, endothelial cells actively maintain a
nonthrombogenic surface through the expression of thrombo-
modulin, heparan sulfate and tissue plasminogen activator.
They also express a number of procoagulants, including tissue
factor, factor V, plasminogen inhibitor, and von Willebrand
factor. The cytokines IL-i, TNF and lymphotoxin can all
increase procoagulant activity: they increase tissue factor-like
activity, decrease thrombomodulin, increase the secretion of
the inhibitor of tissue plasminogen activator and decrease the
secretion of tissue plasminogen activator [33]. These effects
favor the deposition of fibrin and intravascular coagulation. It is
conceivable that pathological levels of IL-i, TNF or lympho-
toxin could promote intraglomerular fibrin deposition and co-
agulation, as is seen in acute forms of glomerulonephritis,
although there is little direct evidence for this as yet.
Interactions of endothelial cells with lymphocytes
The presence of leukocytes within the glomerulus in diseases
with an inflammatory or immune basis suggests that they can
gain access from the capillary lumen via the endothelium. By
analogy with endothelium at other sites, this suggests that
glomerular endothelial cells can be activated by cytokines or
other inflammatory mediators to express appropriate adhesion
molecules. Accordingly, the expression of ELAM- 1, ICAM- 1
and VCAM-1 within the diseased glomerulus has been studied.
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ICAM-l is expressed constitutively by glomerular endothelial
cells and is up-regulated in some forms of necrotizing glomer-
ulonephntis and vasculitis [34, 35]. VCAM-l is expressed by
parietal epithelial cells in normal and diseased glomeruli, but
glomerular endothelial cell expression has not been detected in
a variety of disease states [36] or in renal allografts at the time
of rejection [37]. This contrasts with the inducible expression of
VCAM-l by proximal tubular cells. The reasons for the poor
expression of VCAM-1 on glomerular (and other renal micro-
vascular) endothelial cells is not clear and could reflect pheno-
typic differences or differences in cytokine inducibility. It is
worth noting that glomerular mesangial cells in culture express
large amounts of IL-i inducible VCAM-l despite the fact that
mesangial cell expression of VCAM-l is not detectable in vivo
either (C. Savage, personal observations), suggesting that there
may be active inhibition of mesangial (and possibly endothelial)
cell expression. Similarly, expression of ELAM-i by human
glomerular endothelial cells has not been well-demonstrated in
tissue sections from diseased kidneys, although ELAM-i ex-
pression has been shown on baboon glomerular endothelial
cells following septic shock [331 and also within isolated human
glomeruli following treatment with IL-i for four to six hours
[38]. The dichotomy between the lack of expression of normal
adhesion molecules in disease and the presence of neutrophils,
monocytes and lymphocytes within the glomerulus, raises the
possibility that highly pathological leukocyte transmigration
processes override normal adhesion/transmigration pathways.
For example, in some disease states the endothelium itself may
be damaged to such an extent that it cannot regulate leukocyte
movement.
To examine adhesion molecule expression by human glomer-
ular endothelial cells more precisely requires their isolation and
growth in vitro, but the few reports about successful isolation of
these cells attest to the difficulties of obtaining pure cultures
devoid of mesangial or epithelial cells. Recent reports in this
journal from Green and colleagues suggest that it is possible,
providing that strict selection and culture conditions are used
[39]. A different approach to the problem has been taken by
Ballerman, who has successfully isolated glomerular endothe-
hal cells from bovine kidneys [40]. Studies on human leukocyte
adhesion to bovine glomerular endothelial cells have demon-
strated that neutrophils, monocytes and lymphocytes can all
bind to TNF-activated glomerular endothelial cells through
L-selectin. L-selectin was shown to be of particular importance
for binding of neutrophils under non-static conditions when
integrin (LFA-l, MAC-i) pathways were less effective [41].
In contrast to the difficulty of demonstrating ELAM- 1 and
VCAM-l expression in vivo in human glomerular capillary
loops, MHC class I and II antigens, as well as LFA-3, are
readily expressed [27, 35]. Thus, if the in vitro experiments
which have been performed using human umbilical vein-derived
endothelial cells to demonstrate accessory function for T cell
activation can be extended to glomerular cells in vivo, there is
the possibility that T lymphocytes may be activated while
within glomerular capillaries. In the context of a renal allograft,
such T cell-endothelial cell interactions could initiate vascular
rejection, while within the context of autoimmune glomerular
disease (such as systemic vasculitis) T cell immune responses
could be focused and amplified locally. The ability of monoclo-
nal antibodies against ICAM- 1 to prevent allograft rejection in
nonhuman primates supports the hypothesis that T cell-endo-
thelial cell interactions promote allograft rejection inasmuch as
the principal site of binding was the vascular endothelium [42].
Antibody interactions with endothelial cells
Endothelial cells may contribute to development of glomer-
ular disease if cell surface antigens are recognized by specific
antibody Fab2; Fc receptors are not generally expressed by
endothelial cells although infection by herpes simplex induces
the expression of Fe-like viral glycoprotein gE [43]. Anti-
endothelial cell antibodies have been described in many condi-
tions including diseases associated with glomerulonephritis, for
example, systemic lupus erythematosus, scleroderma, and sys-
temic vasculitis [44]. However, the contribution of such anti-
bodies to vascular involvement in general and to giomerulone-
phritis in particular is unclear, In systemic lupus erythematosus
there is an association between presence of anti-endothelial cell
antibodies and nephritis [45, 46]. Further, there is evidence
that, in some patients, a proportion of anti-endothelial cell
antibodies have anti-phospholipid activity which may encour-
age a procoagulative state of the endothelial surface [47]. For
example, anti-phospholipid antibodies may prevent factor Va
inactivation by binding to the phospholipid substrate provided
by endothelial cells where, in the presence of protein S,
activated protein C can degrade factor Va at an efficient rate
[48].
Endothelial cell injury, through antibody Fc-mediated activa-
tion of complement or engagement of cytotoxic Fe-bearing
leukocytes, has also been sought by several investigators in
systemic lupus, scleroderma and vasculitis [49—52]. In general,
complement-dependent injury has been difficult to demonstrate,
perhaps because of the ability of molecules such as decay-
accelerating factor (DAF), membrane cofactor protein (MCP)
and CD59 to protect endothelial cells against the effects of
homologous complement [53]. Antibody-dependent cellular cy-
totoxicity against endothelial cells has been demonstrated in
some patients with scleroderma [50, 51], in occasional patients
with systemic vasculitis [52], and in a single patient after renal
transplantation [54]. Antibodies to cytokine-inducible determi-
nents of endothelial cells have been described in Kawasaki
disease [55], although glomerular involvement is unusual in this
childhood vasculitis disorder. Antibodies against endothelial
cell determinents which are lost following exposure to IFN-y
have been described in hemolytic uremic syndrome where
glomerular involvement is common [56].
Specific antibodies could also bind to endothehial cells via
antigen bridges where the antigen itself has a high specificity for
endothehial cell binding because of charge or other properties.
This has been described for the DNA-anti-DNA system [57],
and for cationic myeloperoxidase [58, 59] which is a target for
the anti-myeloperoxidase autoantibodies associated with sys-
temic vasculitis [60].
Endothelial cell injury by neutrophils
Neutophils do not normally irreversibly injure endothelial
cells, although there is some increase in vascular permerability
as they adhere and migrate across due to disruption of the
subendothelial basement membrane [61]. However, tissue and
endothelial injury may be severe in circumstances where there
is organ ischemia followed by reperfusion, such as may occur
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after myocardial infarction and after organ transplantation; an
important role for neutrophils has been suggested since deple-
tion of circulating neutrophils attenuates injury [62]. Activated
neutrophils can release oxygen-derived free radicals, proteo-
lytic enzymes and phospholipase products which may injure
tissue [63]. Ischemia is believed to promote neutrophil activa-
tion, accumulation and adhesiveness, and this is supported by
the ability of monoclonal antibodies against CD18 (the integrin
/3 chain) to protect against endothelial damage when the anti-
bodies are administered either before or after ischemia, but
prior to reperfusion [64].
There is also in vitro evidence that neutrophils which have
been activated by ANCA (anti-neutrophil cytoplasm antibod-
ies) can cause endothelial cell injury [65, 66]. Since ANCA are
associated with systemic vasculitis, such observations suggest
links with the pathological vascular wall inflammatory damage
and with the necrotizing capillaritis within the capillary.
Summary
Endothelial cells are active participants in processes control-
ling coagulation, inflammation and immune processes and an
aberration in the controlling mechanisms may contribute to the
development of disease within the glomerulus. The major goal
of the next few years will be to develop reliable and reproduc-
ible methods for isolation and culture of glomerular endothelial
cells so that their properties, and interactions with other gb-
merular cells, may be studied in vitro.
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